Insider · CIK 0001752940
Bo Kruse
Files at YMAB (Y-mAbs Therapeutics, Inc.). First filing May 31, 2024, latest May 31, 2024.
In brief
Bo Kruse files SEC Form 4 as CFO at YMAB (Y-mAbs Therapeutics, Inc.). Since May 31, 2024, Bo Kruse has reported 0 open-market buys worth $0 and 1 open-market sell worth $723k, the latest filed on May 31, 2024.
A track record needs three past buys with six months of prices behind them; Bo Kruse has 0, so none is measured yet.
The newest scored trade: sold $723k of YMAB on May 30, 2024, filed May 31, 2024, scored 53 (moderate).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 53Moderate | Y-mAbs Therapeutics, Inc. | $723k 60,000 shares | -25% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 30, 2024 | YMAB Y-mAbs Therapeutics, Inc. | 60,000 0.14% of outstanding | $722k | May 30, 2024 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 30, 2024 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Common Stock | +28,629 | $2.00 | $57k | 239,506 | May 31, 2024 |
| May 30, 2024 | YMAB Y-mAbs Therapeutics, Inc. | SOpen-market sale Common Stock | -28,629 | $12.03 | $344k | 210,877 | May 31, 2024 |
| May 31, 2024 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Common Stock | +31,371 | $2.00 | $63k | 242,248 | May 31, 2024 |
| May 31, 2024 | YMAB Y-mAbs Therapeutics, Inc. | SOpen-market sale Common Stock | -31,371 | $12.07 | $379k | 210,877 | May 31, 2024 |
| May 30, 2024 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -28,629 | $0.00 | $0 | 271,371 | May 31, 2024 |
| May 31, 2024 | YMAB Y-mAbs Therapeutics, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -31,371 | $0.00 | $0 | 240,000 | May 31, 2024 |
| Jan 18, 2024 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Common Stock | +18,100 | $0.00 | $0 | 210,877 | Jan 22, 2024 |
| Jan 18, 2024 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +108,900 | $0.00 | $0 | 108,900 | Jan 22, 2024 |
Questions about Bo Kruse
Answered from the filings on this page, as of the latest one.
Is Bo Kruse buying or selling?
Not in the last 12 months. Bo Kruse's latest open-market trade on SEC Form 4 was sold $723k of YMAB on May 30, 2024.
How did Bo Kruse's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Bo Kruse has 0.
Where does Bo Kruse file Form 4?
Bo Kruse has filed Form 4 at YMAB (Y-mAbs Therapeutics, Inc.) as EVP, CFO, SECRY & TREAS.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.